Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Crinetics Pharmaceuticals (CRNX) Return on Sales (2017 - 2025)

Crinetics Pharmaceuticals has reported Return on Sales over the past 9 years, most recently at 19.91% for Q4 2025.

  • Quarterly results put Return on Sales at 19.91% for Q4 2025, up 26660.0% from a year ago — trailing twelve months through Dec 2025 was 60.42% (up 22609.0% YoY), and the annual figure for FY2025 was 60.46%, up 22629.0%.
  • Return on Sales for Q4 2025 was 19.91% at Crinetics Pharmaceuticals, up from 909.73% in the prior quarter.
  • Over the last five years, Return on Sales for CRNX hit a ceiling of 10.74% in Q1 2022 and a floor of 909.73% in Q3 2025.
  • Median Return on Sales over the past 5 years was 96.41% (2022), compared with a mean of 160.18%.
  • Biggest five-year swings in Return on Sales: surged 101314bps in 2021 and later crashed -64696bps in 2025.
  • Crinetics Pharmaceuticals' Return on Sales stood at 28.58% in 2021, then crashed by -125bps to 64.39% in 2022, then grew by 19bps to 52.12% in 2023, then tumbled by -450bps to 286.5% in 2024, then soared by 93bps to 19.91% in 2025.
  • The last three reported values for Return on Sales were 19.91% (Q4 2025), 909.73% (Q3 2025), and 112.18% (Q2 2025) per Business Quant data.